A systematic review and economic model of the effectiveness and ...

136
References
children with ADHD: a prospective, randomized,
open-label trial. J Am Acad Child Adolesc Psychiatry
2002;41:776–84.
71. Kupietz SS, Winsberg BG, Richardson E,
Maitinsky S. Effects of methylphenidate dosage in
hyperactive reading-disabled children: I. Behavior
and cognitive performance effects. J Am Acad Child
Adolesc Psychiatry 1988;27:70–7.
72. Manos MJ, Short EJ, Findling RL. Differential
effectiveness of methylphenidate and Adderall ® in
school-age youths with attentiondeficit/hyperactivity
disorder. J Am Acad Child
Adolesc Psychiatry 1999;38:813–19.
73. Michelson D, Faries D, Wernicke J, Kelsey D,
Kendrick K, Sallee FR, et al. Atomoxetine in the
treatment of children and adolescents with
attention-deficit/hyperactivity disorder: a
randomized, placebo-controlled, dose–response
study. Pediatrics 2001;108:E83.
74. Michelson D, Allen AJ, Busner J, Casat C, Dunn D,
Kratochvil C, et al. Once-daily atomoxetine
treatment for children and adolescents with
attention deficit hyperactivity disorder: a
randomized, placebo-controlled study. Am J
Psychiatry 2002;159:1896–901.
75. Michelson D, Buitelaar JK, Danckaerts M,
Gillberg C, Spencer TJ, Zuddas A, et al. Relapse
prevention in pediatric patients with ADHD
treated with atomoxetine: a randomized, doubleblind,
placebo-controlled study. J Am Acad Child
Adolesc Psychiatry 2004;43:896–904.
76. Jensen PS, Arnold LE, Richters JE, Severe JB,
Vereen D, Vitiello B, et al. A 14-month randomized
clinical trial of treatment strategies for attentiondeficit/hyperactivity
disorder. Arch Gen Psychiatry
1999;56:1073–86.
77. Pelham WEJ, Sturges J, Hoza J, Schmidt C,
Bijlsma JJ, Milich R, et al. Sustained release and
standard methylphenidate effects on cognitive and
social behavior in children with attention deficit
disorder. Pediatrics 1987;80:491–501.
78. Pelham WEJ, Greenslade KE, Vodde-Hamilton M,
Murphy DA, Greenstein JJ, Gnagy EM, et al.
Relative efficacy of long-acting stimulants on
children with attention deficit-hyperactivity disorder:
a comparison of standard methylphenidate,
sustained-release dextroamphetamine, and
pemoline. Pediatrics 1990;86:226–37.
79. Pelham WEJ, Carlson C, Sams SE, Vallano G,
Dixon MJ, Hoza B. Separate and combined effects
of methylphenidate and behaviour modification
on boys with attention deficit-hyperactivity
disorder in the classroom. J Consult Clin Psychol
1993;61:506–15.
80. Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ,
Gnagy EM, Chronis AM, et al. A comparison of
Ritalin and Adderall: efficacy and time-course in
children with attention-deficit/hyperactivity
disorder. Pediatrics 1999;103:e43.
81. Pelham WE, Gnagy EM, Chronis AM,
Burrows-MacLean L, Fabiano GA, Onyango AN,
et al. A comparison of morning-only and
morning/late afternoon Adderall to morning-only,
twice-daily, and three times-daily methylphenidate
in children with attention-deficit/hyperactivity
disorder. Pediatrics 1999;104:1300–11.
82. Pelham WE, Gnagy EM, Burrows-Maclean L,
Williams A, Fabiano GA, Morrisey SM, et al. Oncea-day
Concerta methylphenidate versus threetimes-daily
methylphenidate in laboratory and
natural settings. Pediatrics 2001;107:E105.
83. Pliszka SR, Browne RG, Olvera RL, Wynne SK.
A double-blind, placebo-controlled study of
Adderall and methylphenidate in the treatment of
attention-deficit/hyperactivity disorder. J Am Acad
Child Adolesc Psychiatry 2000;39:619–26.
84. Quinn D. Celltech integrated clincial study report. A
multi-centre, double-blind, three arm, parallel group
study comparing the efficacy of immediate release
methylphenidate (Ritalin ® ) and modified release
methylphenidate with placebo in children with attention
deficit/hyperactivity disorder. Slough: Celltech
Pharmaceuticals; 2003.
85. Rapport MD, DuPaul GJ, Kelly KL. Attention
deficit hyperactivity disorder and
methylphenidate: the relationship between gross
body weight and drug response in children.
Psychopharmacol Bull 1989;25:285–90.
86. Schachar RJ, Tannock R, Cunningham C, Corkum
PV. Behavioural, situational, and temporal effects
of treatment of ADHD with methylphenidate. J Am
Acad Child Adolesc Psychiatry 1997;36:754–63.
87. Diamond IR, Tannock R, Schachar RJ. Response
to methylphenidate in children with ADHD and
comorbid anxiety. J Am Acad Child Adolesc Psychiatry
1999;38:402–9.
88. Smith BH, Pelham WE, Evans S, Gnagy E,
Molina B, Bukstein O, et al. Dosage effects of
methylphenidate on the social behaviour of
adolescents diagnosed with attention-deficit
hyperactivity disorder. Exp Clin Psychopharmacol
1998;6:187–204.
89. Spencer T, Heiligenstein JH, Biederman J,
Faries DE, Kratochvil CJ, Conners CK, et al.
Results from 2 proof-of-concept, placebocontrolled
studies of atomoxetine in children with
attention-deficit/hyperactivity disorder. J Clin
Psychiatry 2002;63:1140–7.
90. Steele M, Weiss M, Swanson J, Wang J,
Riccardelli R, Binder C. A randomized, controlled,
effectiveness trial of OROS–methylphenidate compared to
usual care with immediate-release-methylphenidate in
attention-deficit-hyperactivity disorder. A submission to
the National Institute for Clinical Excellence.
London, Ontario: Janssen-Ortho; 2004.